Kodak exits ultrasound miniPACS market

Article

After several unsuccessful attempts to divest its ultrasound miniPACS operations, Eastman Kodak has opted to shut down this business to focus on its full-scale PACS products. Rochester, NY-based Kodak quietly announced in early October that all sales and

After several unsuccessful attempts to divest its ultrasound miniPACS operations, Eastman Kodak has opted to shut down this business to focus on its full-scale PACS products. Rochester, NY-based Kodak quietly announced in early October that all sales and manufacturing of its Access ultrasound miniPACS, ImageVue echocardiography image management system, and Kodak G4 image and information management system would cease by year’s end.

Service and support for these products will continue until the company has transitioned existing customers to other sources or products. The number of employees affected by the discontinued operations is very minor, according to Nancy Sousa, vice president of new business for Kodak’s health imaging division.

Kodak originally got into the ultrasound miniPACS business through a 1994 partnership with Nova Microsonics, then an Allendale, NJ-based subsidiary of ATL Ultrasound (SCAN 2/1/95). Nova developed both ImageVue and Access, which Kodak integrated into its PACS product line. Kodak then acquired Nova Microsonics in 1997 (SCAN 2/19/97), after ATL determined that it was not interested in providing the broad-based image management solutions many of its ultrasound customers were clamoring for.

But Kodak’s acquisition of Cemax-Icon last year as part of Imation’s medical imaging business (SCAN 12/16/98) has led to a change in the company’s image management strategy. Since completing the Imation deal, Kodak has consolidated all of its PACS business into Cemax-Icon (SCAN 3/3/99) but felt that trying to integrate the ultrasound products into Cemax as well was “not the best decision,” according to Sousa.

In addition, both Kodak and Cemax had determined that the growth of the ultrasound miniPACS market has been moderate at best, according to Gary Larson, president of Fremont, CA-based Cemax-Icon.

“The main impact on Cemax is that we now have greater resources to devote to our enterprise-wide PACS business,” Larson said.

Recent Videos
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Can AI Assessment of Longitudinal MRI Scans Improve Prediction for Pediatric Glioma Recurrence?
A Closer Look at MRI-Guided Adaptive Radiotherapy for Monitoring and Treating Glioblastomas
Incorporating CT Colonography into Radiology Practice
What New Research Reveals About Computed Tomography and Radiation-Induced Cancer Risk
What New Interventional Radiology Research Reveals About Treatment for Breast Cancer Liver Metastases
New Mammography Studies Assess Image-Based AI Risk Models and Breast Arterial Calcification Detection
Can Deep Learning Provide a CT-Less Alternative for Attenuation Compensation with SPECT MPI?
Employing AI in Detecting Subdural Hematomas on Head CTs: An Interview with Jeremy Heit, MD, PhD
Related Content
© 2025 MJH Life Sciences

All rights reserved.